Evidence map›Paper›PMID 37386455›Full record

ReviewHealth research policy and systems2023

Gauging innovation and health impact from biomedical research: survey results and interviews with recipients of EU-funding in the fields of Alzheimer's disease, breast cancer and prostate cancer.

Francesca Pistollato, Ivana Campia, Evangelos P Daskalopoulos, Camilla Bernasconi, Christian Desaintes, Sergio Di Virgilio, Christina Kyriakopoulou, Maurice Whelan, Pierre Deceuninck

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Health research policy and systems, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesca PistollatoEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
Ivana CampiaEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
Evangelos P DaskalopoulosEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
Camilla BernasconiEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
Christian DesaintesEuropean Commission, DG Research & Innovation (DG RTD), Brussels, Belgium.
Sergio Di VirgilioEuropean Commission, DG Research & Innovation (DG RTD), Brussels, Belgium.
Christina KyriakopoulouEuropean Commission, DG Research & Innovation (DG RTD), Brussels, Belgium.
Maurice WhelanEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
Pierre DeceuninckEuropean Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy. Pierre.deceuninck@ec.europa.eu.ORCID http://orcid.org/0000-0002-8513-2584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomedical research on Alzheimer's disease (AD), breast cancer (BC) and prostate cancer (PC) has globally improved our understanding of the etiopathological mechanisms underlying the onset of these diseases, often with the goal to identify associated genetic and environmental risk factors and develop new medicines. However, the prevalence of these diseases and failure rate in drug development remain high. Being able to retrospectively monitor the major scientific breakthroughs and impact of such investment endeavors is important to re-address funding strategies if and when needed. The EU has supported research into those diseases via its successive framework programmes for research, technological development and innovation. The European Commission (EC) has already undertaken several activities to monitor research impact. As an additional contribution, the EC Joint Research Centre (JRC) launched in 2020 a survey addressed to former and current participants of EU-funded research projects in the fields of AD, BC and PC, with the aim to understand how EU-funded research has contributed to scientific innovation and societal impact, and how the selection of the experimental models may have underpinned the advances made. Further feedback was also gathered through in-depth interviews with some selected survey participants representative of the diverse pre-clinical models used in the EU-funded projects. A comprehensive analysis of survey replies, complemented with the information derived from the interviews, has recently been published in a Synopsis report. Here we discuss the main findings of this analysis and propose a set of priority actions that could be considered to help improving the translation of scientific innovation of biomedical research into societal impact.

Indexed as

Alzheimer DiseaseBiomedical ResearchBreast NeoplasmsProstatic NeoplasmsHumansMaleRetrospective StudiesAlzheimer’s diseaseBiomedical researchBreast cancerEU fundingImpactIndicatorsNon-animal modelsProstate cancer

Identifiers

PMID37386455
PMCPMC10308747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.